Physicians' Academy for Cardiovascular Education

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Continued benefit of statin treatment after stopping therapy

5' education - July 12, 2021 - Jackie Bosch, PhD

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Reviewing trials with P2Y12 blocker (mono)therapy after ACS

5' education - June 29, 2021 - Prof. Freek Verheugt, MD, PhD

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Patient profiling in HFrEF to tailor therapy

5' education - June 21, 2001 - Pardeep Jhund, MD, PhD

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD

Can targeting of IL-6 lead to CV protection in CKD?

5' education - May 19, 2021 - Prof. Paul Ridker, MD

Renal denervation as option for patients with hypertension despite medications

5' education - May 18, 2021 - Prof. Ajay Kirtane, MD

A call to solve the controversy on omega-3FAs trials

5' education - May 17, 2021 - Prof. Eileen Handberg, PhD

No superiority with NOAC compared to standard care following TAVI

5' education - May 17, 2021 - Jean-Philippe Collet, MD, PhD

Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI

5' education - May 16, 2021 - Prof. Freek Verheugt, MD

No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD

5' education - May 16, 2021 - William Schuyler Jones, MD

12-Months follow up of rapid hs -TnT protocol in ACS suspected patients

5' education - May 16, 2021 - Prof. Derek Chew, MD, PhD

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD
Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.

Alicia Uijl presents the results of an analysis that identified five phenotypic clusters in HFpEF with differences in medication profile, morbidity and mortality.

T2DM-related microvascular disease associated with incident HF

Literature - July 27, 2021 - Kaze AD, et al. - J Am Heart Assoc. 2021

Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.

Where do GLP-1RA fit in in current and future management of CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 26, 2021 - Frederik Persson, MD - Online CME
Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities, Frederik Persson discusses future possibilities for use of GLP-1RA in other target populations.

Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.

Suboptimal use of evidence-based medical therapies in patients with HFrEF and CKD

Literature - July 14, 2021 - Patel RB et al. - J Am Coll Cardiol. 2021

This study showed that prescription rates of evidence-based medical therapies are suboptimal in patients with comorbid HFrEF and CKD, even at eGFR levels where therapies are not contraindicated by kidney dysfunction.

Treatment goals for patients with T2DM and CKD

Subtitling in English, German, Italian, Spanish and French

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

High-dose IV iron decreases occurrence of first and recurrent HF events in patients on hemodialysis

Literature - July 12, 2021 - Jhund PS et al. - JACC Heart Fail. 2021

This analysis of the PIVOTAL trial showed that treatment with high-dose IV iron administered proactively, compared to low-dose IV iron administered reactively, decreased the occurrence of first and recurrent HF events in patients receiving hemodialysis.

Continued benefit of statin treatment after stopping therapy

5' education - July 12, 2021 - Jackie Bosch, PhD
Jackie Bosch presents the results of the HOPE-3 study that show that CV benefits of statin treatment continued for at least three more years after stopping medication in individuals at intermediate risk for CV events.

Jackie Bosch presents the results of the HOPE-3 study that show that CV benefits of statin treatment continued for at least three more years after stopping medication in individuals at intermediate risk for CV events.

Low rates of stroke and bleeding with NOAC in AF patients at extremes of body weight

Literature - July 7, 2021 - Boriani G, et al. - J Clin Med 2021

A subanalysis of ETNA-AF-Europe showed that AF patients using edoxaban who had lower or higher weight than the reference group had similar low rates of stroke and bleeding.

Phase III trial with SGLT2 inhibitor meets primary endpoint in HFpEF

News - July 6, 2021

EMPEROR-Preserved met its primary endpoint and showed a significant risk reduction with empagliflozin for the composite endpoint of time to first event of CV death or HF hospitalization compared to placebo in adults with HFpEF, with or without T2DM.

Heterogenous effect of beta-blockers on all-cause mortality across HFpEF clusters

News - July 6, 2021

ESC HF 2021 The treatment effect of beta-blockers on all-cause mortality in HFpEF patients was heterogenous across clusters of HFpEF, with a significant reduction in the young cluster and the AF-hypertension cluster.

No effect of SGLT2i on six minute walk distance in HFrEF and HFpEF

News - July 6, 2021

ESC HF 2021 Dapagliflozin improved HF symptoms (measured by KCCQ-TSS) in HFrEF compared to placebo, but did not improve physical limitations (measured by KCCQ-PLS) or 6 minute walk distance. No significant improvements with dapagliflozin in any of these outcomes were seen in HFpEF.

Initial results of CRISPR-Cas9-based therapy targeting knockout of TTR gene in ATTR amyloidosis

Literature - July 6, 2021 - Gillmore JD, et al. - NEJM 2021
Administration of NTLA-2001 for //TTR// editing and knockout in patients with hereditary ATTR amyloidosis resulted in large reductions of serum TTR protein levels at day 28.

Administration of NTLA-2001 for TTR editing and knockout in patients with hereditary ATTR amyloidosis resulted in large reductions of serum TTR protein levels at day 28.